Strategic Partnerships Leverage ELIAS Animal Health’s established focus on canine cancer immunotherapies and recent expansion to Lenexa, Kansas to propose collaborations with veterinary oncology practices, animal hospitals, and pet specialty networks for joint trials, distribution, and co-marketing initiatives.

Clinical Leadership Engage with the newly formed Scientific Advisory Board and key personnel hires to position your organization as a collaborator in translational research, clinical study design, and access to expertise for veterinary oncology trials and real-world evidence generation.

Infrastructure Scale With manufacturing expansion in Lenexa and a growing pipeline, target supply chain, contract development and manufacturing organization (CDMO) partners, and logistics providers to support scalable production, cold-chain handling, and timely delivery of canine immunotherapies.

Technology Synergy Offer cloud-based data integration, analytics, and CRM partnerships leveraging their current tech stack (AWS, Google Cloud, Salesforce, Pardot) to optimize trial data management, regulatory reporting, and customer engagement for veterinary oncology programs.

Market Readiness Position ELIAS’s USDA-approved ECI therapy as a market-entry case study for premium canine cancer treatments, and explore collaborations with veterinary distributors and specialty clinics to accelerate adoption, reimbursement strategies, and payer engagement.